<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525616</url>
  </required_header>
  <id_info>
    <org_study_id>2006/101/HP</org_study_id>
    <nct_id>NCT00525616</nct_id>
  </id_info>
  <brief_title>Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid</brief_title>
  <acronym>Rituximab2</acronym>
  <official_title>Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess that it will be possible to control with a single cycle of&#xD;
      rituximab patient with bullous pemphigoid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to assess the efficacy and tolerance of a single cycle of&#xD;
      rituximab in control of bullous pemphigoid.&#xD;
&#xD;
      the main objects are :&#xD;
&#xD;
        1. to assess that a single cycle of rituximab is able to control patient with&#xD;
           corticosteroid-dependent bullous pemphigoid,&#xD;
&#xD;
        2. to avoid the use of corticosteroid in long time,&#xD;
&#xD;
        3. to evaluate duration of control disease and side effect with a single cycle of&#xD;
           rituximab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and biological controls of bullous pemphigoid were estimated every seven days during a period of 1 month and every month during a period of 2 years.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions will be estimated during all the period of this clinical trial</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bullous Pemphigoid</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment consists of two slow intravenous infusions of rituximab 1000mg to 15 days apart with local corticosteroid .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mabthera</intervention_name>
    <description>Two IV perfusions of 1000mg at 15 days intervals</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt;= 18 and &lt; 80&#xD;
&#xD;
          -  karnofsky &gt;= 50%&#xD;
&#xD;
          -  bullous pemphigoid clinical indication&#xD;
&#xD;
          -  cortico-dependent bullous pemphigoid in relapse for the second time&#xD;
&#xD;
          -  contraception used in female patient&#xD;
&#xD;
          -  consent obtained from patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  localized bullous pemphigoid in relapse (&lt;400cm2)&#xD;
&#xD;
          -  pemphigoid of pregnancy&#xD;
&#xD;
          -  dermatosis with IgA&#xD;
&#xD;
          -  pemphigoid with mucous damage&#xD;
&#xD;
          -  pregnant woman or nursing mother&#xD;
&#xD;
          -  woman able to have a baby and without contraception during the clinical trial period&#xD;
&#xD;
          -  age &lt; 18 or &gt; 80&#xD;
&#xD;
          -  karnovsky &lt; 50%&#xD;
&#xD;
          -  significant disease or uncontrolled disease&#xD;
&#xD;
          -  serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody&#xD;
&#xD;
          -  patient with depletion lymphocytic treatment or with initial rituximab treatment&#xD;
&#xD;
          -  unstable angina or ischemic heart disease&#xD;
&#xD;
          -  cardiac insufficiency&#xD;
&#xD;
          -  cardiac rhythm trouble uncontrolled&#xD;
&#xD;
          -  evolutive infection&#xD;
&#xD;
          -  immunodepression&#xD;
&#xD;
          -  neutrophil polynuclear in blood &lt; 1.5 G/l and /or platelet blood concentration &lt; 75G/l&#xD;
&#xD;
          -  positive HIV serology&#xD;
&#xD;
          -  positive hepatitis B and / or C serology&#xD;
&#xD;
          -  concomitant immunodepressor treatment able to induce depletion lymphocytic treatment&#xD;
&#xD;
          -  no consentment&#xD;
&#xD;
          -  antecedent of serious chronic or recurrent infection or other underlying pathology&#xD;
             able to induce serious infection&#xD;
&#xD;
          -  antecedent of deep tissue infection occurred the previous year of inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal JOLY, MD-PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Dermatologique - Hôpital Charles Nicolle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rouen University Hospital, Direction de la Recherche et de l'Innovation,</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>July 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2007</study_first_posted>
  <last_update_submitted>September 5, 2014</last_update_submitted>
  <last_update_submitted_qc>September 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bullous pemphigoid</keyword>
  <keyword>mabthera</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemphigoid, Bullous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

